Longitudinal progression, metrics, age-dependence, and modifiers of ataxia severity in SCA27B: a multicentre study of 219 patients

Yes
The multicentre observational study analysed 661 assessments from 219 people with SCA27B to examine disease progression, clinical outcome metrics and demographic or genetic modifiers.

This multicentre, intercontinental observational study examined 661 assessments from 219 patients with spinocerebellar ataxia 27B (SCA27B), alongside 390 healthy controls, to investigate the Scale for the Assessment and Rating of Ataxia (SARA), longitudinal progression and potential modifiers of disease severity. Overall progression was 0.54 SARA points per year. Gait, stance and lower-limb impairment were the principal contributors to ataxia severity, while ageing-related motor variability and comorbidities affected assessment. The study also found that larger GAA repeat expansions on the shorter FGF14 allele were associated with faster progression.

publication

Year of publication

2026

Source

eBioMedicine

Author

Andreas Traschütz, Ralf-Dieter Hilgers, Friedrich Erdlenbruch, Christel Depienne, Thomas Wirth, Clarisse Delvallée, Astrid Nümann, Catherine Ashton, David Pellerin, Elisabetta Indelicato, Felix Heindl, Mathilde Renaud, Max Borsche, Marcus Grobe-Einsler, Jennifer Faber, Thomas Klockgether, Ludger Schöls, Bernard Brais, Mathieu Anheim, Dagmar Timmann, Matthis Synofzik

You might also be interested in

The Joint Transnational Call is expected to open on 1 December 2026, with an information webinar planned for 14 December.
December 14 @ 3:00 pm - 4:00 pm
This information webinar on the 2027 Joint Transnational Call for Proposals is scheduled for 14 December 2026.
The assessment compares diagnosis, treatment access and national governance across 16 countries, examining gaps in rare disease support throughout the life course.
The document outlines the Call's 2027 proposed research scope, eligibility criteria, consortium requirements and preliminary application timetable for multinational collaborations on recently identified rare diseases.